- High Growth Potential: SOPHiA GENETICS anticipates a revenue increase of 10% to 17% by 2025, driven by innovative products.
- Significant Upside: Analysts predict a potential 144.60% upside from the current share price.
- Outperform Rating: The stock holds an average "Outperform" rating from top brokerage firms.
SOPHiA GENETICS (NASDAQ: SOPH) operates at the forefront of the healthcare software industry, with a current market capitalization of $206.51 million. Despite being unprofitable at present, the company is poised for significant revenue growth, estimating an increase between 10% and 17% by the year 2025. Innovations such as the OncoPortal™ Mutation Tracker are expected to catalyze this growth. Nevertheless, investors focused on stability might be wary due to the stock's high price volatility.
Wall Street Analysts Forecast
The outlook from five industry analysts offers an intriguing perspective on SOPH. The average price target stands at $6.80, with projections spanning a high of $11.00 and a low of $5.00. This average suggests a notable potential upside of 144.60% from the current trading price of $2.78. For a more comprehensive look at these predictions, visit the Sophia Genetics SA (SOPH, Financial) Forecast page.
The consensus among six brokerage firms places SOPHiA GENETICS at an average recommendation of 1.8 on a scale where 1 indicates a "Strong Buy" and 5 suggests a "Sell." This ranking reflects an "Outperform" expectation, highlighting the stock's appeal in the eyes of market analysts.
According to GuruFocus metrics, SOPHiA GENETICS is projected to reach a GF Value of $5.48 in the upcoming year, implying a 97.12% upside from its present price of $2.78. The GF Value represents GuruFocus' estimation of the stock's fair market value, leveraging historical trading multiples and business growth, alongside future performance forecasts. Detailed data is accessible on the Sophia Genetics SA (SOPH, Financial) Summary page.
